Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Shares Issued: 2014-2025

Historic Shares Issued for Viridian Therapeutics, Inc.\DE (VRDN) over the last 11 years, with Sep 2025 value amounting to $11.8 million.

  • Viridian Therapeutics, Inc.\DE's Shares Issued fell 96.91% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.8 million, marking a year-over-year decrease of 83.00%. This contributed to the annual value of $453.7 million for FY2024, which is 262.73% up from last year.
  • According to the latest figures from Q3 2025, Viridian Therapeutics, Inc.\DE's Shares Issued is $11.8 million, which was up 1,452.29% from $763,000 recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's 5-year Shares Issued high stood at $382.7 million for Q3 2024, and its period low was $4,000 during Q2 2022.
  • Its 3-year average for Shares Issued is $54.0 million, with a median of $2.3 million in 2025.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Shares Issued tumbled by 99.95% in 2022 and then surged by 53,725.74% in 2024.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Shares Issued (Quarterly) stood at $32.4 million in 2021, then declined by 22.57% to $25.1 million in 2022, then skyrocketed by 359.57% to $115.3 million in 2023, then crashed by 39.36% to $69.9 million in 2024, then tumbled by 96.91% to $11.8 million in 2025.
  • Its Shares Issued was $11.8 million in Q3 2025, compared to $763,000 in Q2 2025 and $2.3 million in Q1 2025.